Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022
Global Health Economics and Sustainability · 2023
DOI: 10.36922/ghes.0995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Health Economics and Sustainability, 2023. Verfasst von Marcus Carvalho Borin und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Prompt release of novel pharmaceuticals is very much sought after during critical circumstances to aid patients and society in need. Nonetheless, the expeditious availability of these medications may jeopardize the well-structured investigations and observations. To tackle this concern, regulatory agencies globally have implemented expedited registration procedures. In Brazil, the National Health Surveillance Agency (Anvisa) has likewise implemented an expedited registration process to cater to patients who cannot afford to wait. The objective of this study is to evaluate the impact of Anvisa’s accelerated drug registration on the challenging regulatory environment in Brazil. Data pertaining to medications registered by Anvisa from 2017 to 2022 through the expedited process were procured from the Federal Government’s transparency portal and the medication consultation portal. The registration of novel drugs by Anvisa through both standard and expedited processes during this timeframe was analyzed. The introduction of the accelerated registration regulation by Anvisa in 2017 led to a substantial rise in registration requests utilizing this regulatory modality. Furthermore, the data concerning drug registration through all channels unveiled a noteworthy reduction in average response time. Despite concerns pertaining to the effectiveness and safety of drugs registered through the expedited process, often reliant on Phase II studies, the utilization of this process is on the rise worldwide, including in Brazil. To ensure the sustainability of health-care systems, it may be advantageous to implement provisional registration in conjunction with subsequent evaluation through real-world studies and financing based on risk-sharing agreements. In conclusion, the accelerated drug registration process implemented by Anvisa in Brazil has exhibited promising results in terms of reduced response times. Nevertheless, the effectiveness and safety of drugs registered through this process necessitate meticulous evaluation. The implementation of provisional registration and the integration of real-world studies, alongside managed entry agreements, could offer a sustainable alternative for health-care systems.
Zitieren
APA
Borin, M. C., Barbosa, M. M., Pereira, C. O., Martins, C. R., Reis, D. P. D., Ribeiro, G. J. C., Tupinambás, J. T., Zocrato, K. D. C., Carvalho, L. M. D. A., Freitas, A. P. D., Horta, M. D. G. C., Talim, M. C. T., Azevedo, E. G. D., Bersan, S. A. L., & Kelles, S. M. B. (2023). Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022. Global Health Economics and Sustainability. https://doi.org/10.36922/ghes.0995
Vancouver
Borin MC, Barbosa MM, Pereira CO, Martins CR, Reis DPD, Ribeiro GJC, et al. Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022. Global Health Economics and Sustainability. 2023. doi:10.36922/ghes.0995
BibTeX
@article{Borin2023,
author = {Borin, Marcus Carvalho and Barbosa, Mariana Michel and Pereira, Camila Oliveira and Martins, Carina Rejane and Reis, Daniel Pitchon dos and Ribeiro, Geraldo José Coelho and Tupinambás, Júlia Teixeira and Zocrato, Karina de Castro and Carvalho, Lélia Maria de Almeida and Freitas, Arcela Pinto de and Horta, Maria da Glória Cruvinel and Talim, Mariza Cristina Torres and Azevedo, Ernesto Gomes de and Bersan, Sergio Adriano Loureiro and Kelles, Silvana Marcia Bruschi},
title = {Assessing the impact of fast-track drug registration by Anvisa in Brazil: A descriptive study of new drug registrations from 2017 to 2022},
journal = {Global Health Economics and Sustainability},
year = {2023},
doi = {10.36922/ghes.0995}
}
EUVIMED